The FDA rejected Capricor Therapeutics’ deramiocel (a cell therapy for Duchenne muscular dystrophy) for a second time, according to the latest reporting. The decision blocks the program from reaching the market, despite a pivot to a narrower patient group within Duchenne. Both randomized clinical studies reportedly failed to demonstrate deramiocel’s ability to prevent heart failure or preserve upper-limb muscle function in the evaluated populations. The repeated negative regulatory outcome increases pressure on Duchenne developers to strengthen evidentiary packages and endpoint alignment. For the market, the immediate impact is risk repricing around deramiocel and renewed attention on what constitutes sufficient clinical differentiation in Duchenne, particularly for therapies aiming to alter progression in specific functional domains.
Get the Daily Brief